What is one possible consequence of failure to follow current good manufacturing practices?

The potential consequence of failure to follow current good manufacturing practices (CGMP) is that the drug could become adulterated. Adulteration refers to a situation where the drug does not conform to standards of quality, strength, or purity set by regulatory authorities. This can occur if manufacturing practices do not comply with established guidelines, leading to contamination, degradation, or other quality issues that compromise the drug's safety and efficacy.

Adherence to CGMP is essential in ensuring that drugs are consistently produced to high-quality standards. If these practices are neglected, the resulting products can be unreliable and dangerous, impacting both patient safety and public health. Thus, identifying a drug as adulterated highlights a critical concern regarding the manufacturing process and its adherence to regulations designed to ensure drug safety and effectiveness.